1. A composition for an anti-cancer vaccine for transdermal administration for use in the induction of cellular immunity, comprising: (i) a WT1 peptide and / or a modified WT1 peptide； and (ii) a first stimulator of the induction of cellular immunity, which is a pharmacologically acceptable acid or its pharmacologically acceptable salt. The anti-cancer vaccine composition for transdermal administration according to claim 1, wherein the composition is intended for use in the treatment of a malignant tumor. The anti-cancer vaccine composition for transdermal administration according to claim 1, wherein the pharmacologically acceptable acid or its pharmacologically acceptable salt is an organic acid or its pharmacologically acceptable salt. The anti-cancer vaccine composition for transdermal administration according to claim 3, wherein the organic acid or a pharmacologically acceptable salt thereof is an organic compound having a carboxy group or an organic compound having a sulfo group or a pharmacologically acceptable salt thereof. The anti-cancer vaccine composition for transdermal administration according to claim 3, wherein the organic acid or its pharmacologically acceptable salt is a straight or branched chain saturated or unsaturated fatty acid in which the straight chain saturated portion has from 8 to 20 carbon atoms, lactic acid, malic acid, salicylic acid, maleic acid, citric acid, an organic compound having a sulfo group or a pharmacologically acceptable salt thereof. 6. The anti-cancer vaccine composition for transdermal administration according to claim 3, wherein the organic acid or its f1. Композиция противораковой вакцины для трансдермального введения для применения в индукции клеточного иммунитета, содержащая:(i) пептид WT1 и/или модифицированный пептид WT1； и(ii) первый стимулятор индукции клеточного иммунитета, который представляет собой фармакологически приемлемую кислоту или ее фармакологически приемлемую соль.2. Композиция противораковой вакцины
